Introduction.Chronic obstructive pulmonary disease (COPD) remains one of the major health problems nowadays. The aim of the research was to increase the treatment efficiency for COPD group B patients by using antibiotics, mucolytics, topical nebulizer therapy and halotherapy sessions in combination therapy. The study enrolled 70 COPD group B patients, the average age of patients was 59.6±2.2 years. The diagnosis was made in accordance with the Order of the Ministry of Public Health of Ukraine as of June 27, 2013 № 555.Patients were divided into two groups. Patients of the first group (control, n=35) received basic therapy - azitrox 500 mg once day, acetylcysteine 200 mg - 2 times daily and combination bronchodilator therapy in the form of dose inhalercontaining fenoterol hydrobromide 50 mcg and ipratropium bromide 20 mcg (berodual H) - 2 times a day, anti-inflammatory therapy in the form of turbuhaler budesonide (pulmicort) 100 mcg twice a day for 7 days. Patients of the second group (main group, n=35) in addition to the basic therapy were prescribed double nebulizer therapy with the compressor nebulizer NEB-10 "Microlife" 2 times a day containing combined broncholytic agent fenoterol hydrobromide with ipratropium bromide (2 Freimid) diluted in 2 ml of saline; solution of budesonide (Pulmicort) nebulized 2 x 0.5 ml mg / mL=1.0 mg, dissolved in 2 ml of saline - 2 times a day №7; and additionally, starting on day 4, halotherapy sessions. Thus, the proposed combined therapy of COPD group B patients is more advanced and rational, it improves the effectiveness of basic medical therapy by optimizing the recovery and rehabilitation process, which has a positive effect on the improvement of the seven components of QOL, it is well tolerated and does not cause side effects.